The EHA research roadmap: Malignant lymphoid diseases Editorial


Authors: Dreyling, M.; André, M.; Gökbuget, N.; Tilly, H.; Jerkeman, M.; Gribben, J.; Ferreri, A.; Morel, P.; Stilgenbauer, S.; Fox, C.; Ribera, J. M.; Zweegman, S.; Aurer, I.; Bödör, C.; Burkhardt, B.; Buske, C.; Caballero, M. D.; Campo, E.; Chapuy, B.; Davies, A.; de Leval, L.; Doorduijn, J.; Federico, M.; Gaulard, P.; Gay, F.; Ghia, P.; Grønbæk, K.; Goldschmidt, H.; Kersten, M. J.; Kiesewetter, B.; Landman-Parker, J.; Le Gouill, S.; Lenz, G.; Leppä, S.; Lopez-Guillermo, A.; Macintyre, E.; Mateos Mantega, M. V.; Moreau, P.; Moreno, C.; Nadel, B.; Okosun, J.; Owen, R.; Pospisilova, S.; Pott, C.; Robak, T.; Spina, M.; Stamatopoulos, K.; Stary, J.; Tarte, K.; Tedeschi, A.; Thieblemont, C.; Ulrich Trappe, R.; Trümper, L. H.; Salles, G.
Title: The EHA research roadmap: Malignant lymphoid diseases
Keywords: minimal residual disease; guidelines; marginal zone lymphoma; positron-emission-tomography; acute lymphoblastic-leukemia; b-cell lymphoma; chronic lymphocytic-leukemia; clinical-practice; open-label; diagnosed multiple-myeloma; stage hodgkins lymphoma
Journal Title: HemaSphere
Volume: 6
Issue: 6
ISSN: 2572-9241
Publisher: Lippincott Williams & Wilkins  
Date Published: 2022-06-01
Start Page: e726
Language: English
ACCESSION: WOS:000797600900001
DOI: 10.1097/hs9.0000000000000726
PROVIDER: wos
PMCID: PMC9126526
PUBMED: 35620592
Notes: Editorial Material -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gilles Andre Salles
    269 Salles